Breast Cancer

New Study Further Supports Safety of Promensil(R) as a Natural, Effective Way to Manage Mild-to-Moderate Menopausal Symptoms

Published in Cancer Weekly, April 29th, 2008

Natrol, Inc., the exclusive U.S. licensee for Promensil(R) and a premier marketer and manufacturer of nationally branded nutritional products, announces the results of a large, three-year study -- published in the journal Menopause International -- reinforcing the safety of this red clover isoflavone supplement for managing hot flashes and other menopausal symptoms.(1)(a)

Furthermore, this new study shows that Promensil, containing a standardized supplement of red clover isoflavones, has a neutral effect on breast density in women with a family history of breast cancer. This is in contrast to studies showing that some conventional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2008-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry